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Abstract 
BACKGROUND  
The purpose of this study is to assess the efficacy in reduction in posterior capsule 
opacification following cataract surgery by the use of Xylocaine brand of lidocaine 
1% unpreserved 1 mL as hydrodissection fluid replacing balanced salt solution.  
METHOD  
The author performed all surgeries without any change in lens design or operative 
technique except for the change in hydrodissection fluid. There was no increase in 
complication rate of surgeries performed with Xylocaine as compared to those with 
balanced salt. The efficacy of the change in technique was assessed by the change 
in incidence of neodymiun:yttrium alluminium garnet (Nd:YAG) laser requirement 
which was separately assessed by an independent ophthalmologist. Minimum 
follow up exceeds two years with a maximum of eight years.  
RESULTS  
Xylocaine hydrodissection in this series did not reduce the already decreasing 
incidence of posterior capsule opacification at the 2 year review. The ‘p’ value was 
0.855 representing no significant difference. The result must be seen against the 
general improvement worldwide and also by the author in the reduction of 
posterior capsule opacification to less than 5% over the years by improving 
operative techniques, lens materials and lens designs. 
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CONCLUSION  
Hydrodissection with unpreserved Xylocaine 1%  mL is safe, and cheap and 
requires no change in surgical technique. 
Xylocaine is known to be toxic to some bacterial cells and in a dose dependent 
relationship with corneal endothelial cells. A further larger double masked 
prospective trial would cover a shorter time span and eliminate the comparison 
with an overall trend line. There are very few safe pharmacological methods 
currently available clinically for PCO reduction and none in common use.  
KEYWORDS  
Cataract surgery, posterior capsule opacification, Xylocaine unpreserved brand of 
lidocaine local anaesthetic.  
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CHAPTER 1  
Introduction  
The hypothesis involved is that the opacity that occurs in the posterior capsule 
following some lens surgeries can be reduced by using Xylocaine brand of 
unpreserved lidocaine 1% 1 mL during the hydrodissection technique. The 
preparation is the product of Astra-Zeneca (Sydney Australia) and is used 
throughout this surgical series. It is strongly recommended that the findings herein 
be not transferred to any other product branded as “equivalent” or “generic” 
because there are issues with pH, osmolality and buffers in other preparations 
which may be toxic to the corneal endothelium as will be discussed later. (Spalton, 
1999) In quoting references, the original words of the author whether lidocaine, 
lignocaine or Xylocaine are used and no transposition is assumed. 
The word “cataract” describes the opacification of the crystalline lens of the eye. 
The word owes its origin to the erroneous belief that a sort of curtain fell down like 
a waterfall from the “humour” of the brain.(May and Worth, 1954) In fact,the lens 
protein becomes denatured and disrupted destroying the optical clarity. 
The importance of a good long term surgical result is emphasised by taking a 
global view of the problem. Cataract is the most common cause of treatable 
blindness in Australasia and most of the world and posterior capsule opacification 
post operatively is the most common unwanted result. The essential success of any 
lens surgery lies in maintaining a perfectly clear posterior capsule permanently. 
(Findl et al., 2007) (Pandey et al., 2004, Apple et al., 2001, Apple et al., 2000)  Any technique that improves 
the permanent clarity of the capsule, even by a small percentage, benefits the 
individual and the community both socially and economically.  
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Although often overlooked, vision loss must be one of the archetypal chronic 
diseases of adults. (Taylor et al., 2007) 
Cataract surgery “is now extraordinarily successful”. (Taylor and Keefe, 2002) “Cataract 
removal and intraocular lens (IOL) implantation is by far the most common and 
one of the most successful of all operations in all of medicine”(Survey of Ophthalmology 
Editors, 2000) and probably the most common surgery performed around the world 
each day because there is no effective medical treatment for cataract.(Toh et al., 2007).. 
Surgeons in India perform more than 4 million operations each year.(Nirmalan et al., 
2006) 
Cataract is usually due to ageing but may also follow trauma, intraocular or 
systemic inflammation, systemic metabolic diseases (especially diabetes mellitis), 
corticosteroid therapy (local or systemic), congenital and hereditary factors, 
irradiation (including Ultraviolet), and smoking. Multiple risk factors may be 
operative in any one individual. Some causes are still unknown(West, 2007). A survey 
among older Australians estimates that at least 444,400 persons aged over 55 years 
are visually impaired to some extent, representing 9.4% of that group. Senile 
cataract is the largest subgroup.(Bennet and Australian Institute of Health and Welfare, 2005)  
The incidence of clinically significant cataract reaches almost 50% of persons over 
75 years because of reduced visual acuity and contrast sensitivity and glare 
interfering with function.(Bennet and Australian Institute of Health and Welfare, 2005)  
The definition of ‘legally blind’ (that is entitlement to a disability pension on the 
basis of vision loss) is central vision of less than 6/60 (Snellen) corrected in the 
better eye. (allowance can also be made for visual field defects). Centrelink 
Australia records indicate that 0.8% of all pension recipients are in this category. 
But this underestimates the true number as many were receiving a pension before 
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they became legally blind and the reclassification is not done, as it may make no 
difference to their pension payment. (Bennet and Australian Institute of Health and Welfare, 2005) 
In USA, over the years 1991-1999, “the clinical diagnosis of major chronic eye 
diseases associated with ageing increased dramatically in a longitudinal sample. At 
the end of nine years, nearly half of the sample of surviving US Medicare 
beneficiaries had at least one of these diseases.(Lee et al., 2003)  
Cataract is the main treatable cause of visual loss but others are age related macular 
degeneration (AMD), glaucoma and diabetic retinopathy and these may all occur 
coincidentally. This means that even after a technically successful cataract surgery 
the vision may still be impaired to some degree if there is comorbidity. Long term 
cigarette smoking and Ultraviolet-B exposure bring on cataract earlier and 
probably are summative in effect.(Bennet and Australian Institute of Health and Welfare, 2005)  
The impact of the visual loss on the individual can be severe, causing not only 
depression because of isolation, loss of quality of life, loss of independence, social 
relationships and sensory stimulation, but also increasing the risk of falls and 
injury with subsequent hospitalisation and costs to the community.(Bennet and Australian 
Institute of Health and Welfare, 2005), (Klein et al., 2006, Owsley and McGwin, 2007) The health system cost 
of cataract surgery per person in Australia in 2005 was $178.(Access Economics, 2008) 
The importance of keeping the ageing population independent of government and 
volunteer services has been emphasised recently by the Australian Government’s 
programmes to assist in keeping older Australians at home for as long as possible 
rather than admission to hospital or hostel. The burden of dependence of this group 
of persons on external care is not only in the cost of services provided by 
government agencies but in the immeasurable cost of volunteer help and the 
restriction of employment on family members acting as volunteers or carers who 
10 
would otherwise be in the workforce. This restriction on the life of carers has a 
cumulative effect on their future lives by limiting their work experience and 
therefore job opportunities when their care role ends. 
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CHAPTER TWO  
History and Perspectives  
The identification of cataracts goes back at least to the code of Hammurabi in 
Babylon around 2000 BC. The Egyptians around 1600 BC wrote of the problem 
and their techniques appear to be variations on couching (that is pushing the 
complete lens into the vitreous by rupturing the zonule after inserting a broad knife 
through the corneoscleral junction of the eye). This technique may have been 
brought from Greece at the time of Alexander when he invaded Egypt in 336 BC. 
This technique was also mentioned by the Roman, Celsus around 25AD probably 
with little change.(Porter, 1996, Oguz et al., 2004, Chua, 2000) The Turkish surgeon Serefeddin 
Sabuncouğlu (1385-1468) performed cataract surgery using sharp pointed straight 
flat forceps instead of a knife for the incision then couching the cataract into the 
vitreous with the same instrument slightly opened.(Oguz et al., 2004)  
Extraction of the opaque lens was probably practised in the 17th and 18th centuries 
in Europe but the practitioners guarded their knowledge against competitors and 
documentation is poor.  
About this time a more scientific approach to medicine was emerging and it was 
widely accepted that the cause of the cataract was not washing down of the 
cerebral fluid into the eye from the brain but that the opacity was in the lens itself. 
Removal of the opaque material was performed in France in 1722 by Mery and 
later Daviel in 1748, the latter being commonly credited with the honour. By 
making a large incision in the eye at the limbus and then, after opening the anterior 
capsule with serrated forceps, the opaque material was expressed. Sutures were not 
possible and the patient’s head needed to be kept immobile (and bowels confined) 
for 2 weeks. (Chua, 2000) This left the patient aphakic and with a need of thick 
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spectacles of at least +10 dioptres for distance and separate stronger reading 
glasses. This was the beginning of extracapsular lens extraction without implant 
and without sutures. Fine sutures were not then available so human hair was later 
used. Despite the large incision many patients benefited though complications were 
common. The technique reached its peak with the work of Von Graefe and his 
famous cataract knife. The impressionist painter Monet had one successful cataract 
removal and subsequently revised his famous paintings of the bridge in his garden 
in Giverny because the brown cataract had filtered the blue end of the colour 
spectrum from his vision.(Ravin, 1985) This retouching confused analysts of his work 
who were unaware of the changes.(Hale, 1975) 
Posterior capsule opacification certainly occurred after many of these operations 
and attempts were made to incise (needling) the opacity post operatively to clear 
the visual axis. The Ziegler knife has a small crescent tip on a thin tapering shaft 
which could be inserted at the limbus without the loss of aqueous and cut the 
posterior capsule on two sides of a triangle folding it backwards then into the 
vitreous on the third side.  
Older 20th century text books in English such as Torok E 1913, Parsons JH 1918, 
Stallard HB 1946, May and Worth 1954,(Torok and Grout, 1913, Parsons, 1918, Stallard, 1946, May 
and Worth, 1954) all mention posterior capsule opacification as a complication of the 
surgery but the incidence is not well documented and may be as high as 50%. The 
problem may still be as high as 80% in surgery for congenital cataracts even with 
current techniques.  
! 1  
All of these early operations were performed without anaesthetic until the use of 
cocaine topically by Koller in 1884 on the suggestion of Sigmund Freud.(Chua, 2000)  
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Lidocaine and other currently used local anaesthetics are chemical modifications of 
naturally occurring narcotics.(Ruetch et al., 2001) 
Sir Harold Ridley implanted the first intraocular lens after extracapsular cataract 
extraction (ECCE) at St Thomas’ Hospital London England in 1949(Apple, 2000, Survey 
of Ophthalmology Editors, 2000) publishing his results in 1951,(Ridley, 1951) recording the 
problem of posterior capsule opacification. His peers did not receive his technique 
enthusiastically at that time.  
Intracapsular cataract extraction (ICCE) that is, removing the whole of the cataract 
and its capsule in one piece was an attempt in the middle of the 20th century to 
avoid the problem of posterior capsule opacification and is attributed anecdotally 
to Col. Smith(RANZCO/RVEEH Museum, 2005), a British surgeon working in the Indian 
medical service. This brought it’s own complications and is rarely used now.  
Current cataract surgery technique is a modification of the techniques proposed by 
Charles Kelman in about 1967. It now consists of a self sealing incision of less 
than 3mm and introduction of a viscoelastic fluid into the anterior chamber. This is 
followed by the removal of a 5-6mm circle of anterior capsule by continuous tear, 
hydrodissection of the capsule away from the cataract. Removal of the cataract is 
by various techniques based on phacoemulsification (ultrasound), irrigation and 
aspiration of any remaining material and a foldable intraocular lens is inserted into 
the capsular bag. Sutures are not routinely used. In situations where 
phacoemulsification is not available, manual techniques with small incisions can 
give comparable results but recovery times may be longer. 
. 
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Figure 1 – Cataract and intraocular lens 
 
 
Figure 1. Showing the position of the natural lens behind the iris and of the 
implanted lens prosthesis in the capsular bag remaining after the irrigation and 
aspiration of the cataract through an anterior capsular opening (capsulorhexis).. 
The natural lens zonules (suspensory ligaments) support both structures. The 
posterior part of the lens capsule remains preventing displacement of the implanted 
lens into the vitreous. 
Cataract IOL
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Permanent increase in visual acuity after surgery depends on the posterior capsular 
bag remaining clear and intact.(Findl et al., 2007) Medical treatment of cataract is not 
possible at this time. 
Demand for cataract surgery will continue to increase with time because of the 
ageing population and increasing life expectancy in all countries. Maldistribution 
of the availability of cataract surgery across any country, and sadly, lack of money 
aggravate the waiting times. The ageing ophthalmic surgeon population in 
Australia and financial restriction on the number of surgeries performed in public 
hospitals add to increasing backlogs.  
The Australian Department of Health and Ageing, from various sources, estimates 
that the number of cataract operations in the general population increased threefold 
from 1989 to 1997 and the need will double over the subsequent 20 years.(Taylor and 
Keefe, 2002) The estimated cost of cataract operations in the 2003 fiscal year was 
AU$378million of which Medicare Australia rebated AU$47,718,000. With the 
inclusion of outpatient visits, drugs and ancillary expenses this reaches AU$1.9 
billion annually. Estimated figures vary from Medicare Australia statistics because 
some surgeries are not claimed and/or rebated under Medicare. The operation rate 
was 6.2 per 1000 population compared with 7.26 in Sweden and 4.75 in England 
and increasing in all three countries.(Taylor, 2007)  
In Australia, the incidence of Medicare funded cataract surgery is increasing (but 
not fast enough to cope with need), whereas the incidence of Nd:YAG laser 
capsulotomy is not increasing reflecting better surgical results as shown in Figure 
2. The costs are in Figure 3 and the trend in Figure 4.  
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Cataract surgery may cost as little as US$15 per disability adjusted life year 
(DALY) in developing countries and is still cost effective at US$2020 in developed 
countries.(Taylor et al., 2007) 
One million Nd:YAG capsulotomies cost USA Medicare US$250million in 
2001.(Schmidbauer et al., 2001) Value based cost-utility analysis over the years 1992-2003 
in USA concluded that “the majority of ophthalmic interventions are especially 
cost effective by conventional standards” and the median cost utility was 
US$5,219/qua1ity adjusted life year (QALY).(Brown et al., 2004) Unfortunately differing 
bases for assessment of benefit make strict comparisons difficult and costs vary 
from lower in Europe and Canada to higher in USA. In both relative and absolute 
terms, cataract surgery is cost effective compared with other common operations 
such as hip and knee surgery and defibrillator implantation.(Landsingh et al., 2007) Cataract 
also increases mortality and systemic morbidity.(Cugati et al., 2007)  Cataracts “are 
associated with some measures of frailty (that are) independent of visual acuity and 
systemic comorbidities.” (Klein et al., 2003, Klein et al., 2006, Bennet and Australian Institute of Health and 
Welfare, 2005, Walker et al., 2006)      
Bulletin of the World Health Organisation in 2004 concluded that “extracapsular 
surgery (ECCE) for cataracts at a high level of coverage is the most effective way 
of restoring sight in all epidemiological subregions considered”.(Baltussen et al., 2004) 
This is supported by a Cochrane Collaboration review.(Riaz et al., 2006) This same 
review found that “ECCE with a posterior chamber lens implant provides better 
visual outcome than intracapsular extraction with aphakic glasses or anterior 
chamber intraocular lens”. Unfortunately, costs put cataract surgery beyond reach 
for many millions in the world. This is still true whether paid by the individual or 
the state or shared or subsidised by volunteer surgeons and support workers and 
organizations. The Cochrane Collaboration drew up a protocol in 2006 for a 
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systemic review assessing interventions for preventing posterior capsule 
opacification and reported in 2007.(Findl et al., 2002, Findl et al., 2007). 
The results of cataract surgery with IOL implant has been improving particularly 
over the last 10 years. This applies to both the intraoperative and long term 
performance (Figures 2,3 and 4) and is a world wide trend. Reliable statistics for 
countries without access to phacoemulsification are hard to find but verbal reports 
from surgeons who visit confirm improvement there also. 
As the incidence of posterior capsule opacification after elective 
phacoemulsification surgery is now often below 5% and reducing, we must look 
towards ways other than surgical technique, IOL design and IOL materials to 
approach the ideal of a permanently clear posterior capsule after every operation. 
Medical methods for the prevention and treatment of cataract are currently in their 
infancy and are reviewed below. Considering the above costs, any improvement in 
surgical technique, however small, resulting in reduced need for posterior 
capsulotomy has large global and individual socio-economic benefit. 
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Figure 2 – Medicare Australia – Number of services provided 
January 1997 to December 2007 for cataracts (42702) and 
Nd:YAG (42788) 
 
Figure 2. Medicare Australia Figures showing the increasing number of cataract 
surgeries performed in Australia over the years 1997-2007 compared with the 
steady rate of posterior capsulotomy for the same years.  This confirms the overall 
reduction in percentage of operations requiring capsulotomy.  
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Figure 3 – Medicare Australia - Benefits paid from January 1997 
to December 2007 for cataract surgery (42702) and Nd:YAG 
laser (42788) 
 
Figure 3. The same years as Figure 2 reflecting the reduced cost of capsulotomies 
as a percentage of the cost of surgeries.   
In both Figures the dip in December quarter each year is due to hospital closures 
for maintenance and to staff holidays. 
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Figure 4 – Clinical incidence trend of posterior capsule 
opacification (PCO) 1980 to 2000 (various sources)(Pandey et al., 2006) 
 
Figure 4. Reducing incidence of capsulotomy over a range of sources covering the 
years 1980-2000.  This trend continues but possibly more slowly. 
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Figure 5 – Clear red reflex from the retina after Nd:YAG 
capsulotomy 
 
Figure 5. Photograph from the front of the eye after both cataract extraction with 
intraocular lens implantation followed by laser posterior capsulotomy. The IOL is 
not seen as it is transparent but the difference in transparency between the opaque 
capsule (labelled PCO) and the opened capsule (labelled edge of the capsulotomy) 
is obvious. The patient would have experienced a marked increase in central and 
peripheral best corrected visual acuity (BCVA) after capsulotomy. 
Edge of 
Posterior 
Capsulotomy 
PCO 
Anterior 
Capsulorhexis 
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CHAPTER THREE  
The scope of the posterior capsule opacification 
problem  
The enduring success of any lens surgery depends on the permanent clarity of the 
posterior capsule no matter which surgical technique is used otherwise the vision 
becomes blurred again and sensitivity of the macula of the retina is reduced.(Varga et 
al., 2007)  
In developed countries, the next most common surgical procedure after IOL is 
laser to clear any opacity that may occur in the posterior capsule.(Taylor and Keefe, 2002) 
This improves both best corrected visual acuity (BCVA) and sensitivity of the 
macula.(Varga et al., 2007) 
Sourdille (a French ophthalmologist) is quoted on the importance of the subject; 
“isn’t it intriguing to read reports on the remarkably low incidence of posterior 
capsule opacification (PCO) after cataract surgery and to learn simultaneously that 
Neodymium:yttrium-aluminium-garnet (Nd:YAG) laser capsulotomy is the second 
most frequently performed surgery in some industrialised countries”.(Emery, 1999) 
This is partly explained by the lag time of years between IOL implantation and 
need for Nd:YAG laser. There is a marked and continuing decrease in Nd:YAG 
laser capsulotomy rates since that quote in 2001 due to better surgical technique, 
better lens designs and improved materials.  (Apple et al., 2001, Schmidbauer et al., 2001) “PCO 
has impeded the spread of successful cataract surgery and IOL implantation to the 
25 million persons (and ll0 million persons with visual disability) worldwide with 
cataract, by far the most common cause of visual impairment”.(Schmidbauer et al., 2001)  
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FIGURE 6 – Embryological development of the eye (McAvoy et al., 2000) 
 
Figure 6.sections through the developing eyes of e10-14 rat embryos stained with 
haematoxylin and phloxine. At e10 (a) bilateral outgrowths from the developing 
brain form the optic vesicles (ov). In early e11 embryos (b) the optic vesicle is 
closely associated with a region of head ectoderm that is destined to form lens. In 
the late e11 embryo (c) both the ectoderm and the neuroectoderm are thickened 
along the region of close proximity, forming the lens placode (lp) and retinal disc 
(rd), respectively. Invagination of lens placode and optic vesicle at day 12 (d) leads 
to the formation of the lens pit (lp) and optic cup (oc), respectively. By e13 (e) the 
lens vesicle (lv) has formed and detached from the optic cup (oc). The posterior 
lens vesicle cells elongate to form primary lens fibre cells leading to narrowing of 
the vesicle lumen. By e14 (f) the lens vesicle lumen has disappeared and the 
primary lens fibres (lf) are in contact with the anterior lens vesicle cells which form 
the epithelium (e). Vitreous humour (vit) and hyaloid vasculature forms between 
the developing lens and retina. The inner layer of the optic cup will form the neural 
retina (nr). Adapted from de Longh and McAvoy. 8 scale bars: (a) 50 μm; (b,c) 75 
μm; (d–f) 100 μm.. 
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To understand how lens epithelial cell proliferation occurs inside a cavity lined by 
endothelial cells requires a review of the embryology. Very early in embryonic 
development a plaque of ectoderm becomes intimately associated with the cranial 
end of the developing neural tube. This invaginates maintaining the intimate 
contact so that the plaque is surrounded by a doughnut of ectoderm rising up to 
enclose the lens epithelial plaque to form the anterior segment of the eye. This 
ectodermal cell plaque forms the lens of the eye which continues to grow 
throughout life, albeit very slowly, in both axial and equatorial meridia. The lens 
cells align themselves in an antero-posterior direction under the influence of 
growth factors and become so thin they are called fibres and the nuclei are all 
under the anterior capsule resulting in best optical clarity.  
This ectodermal-neural integration means that the optic nerve (cranial nerve II) is 
in fact brain being third order neuron. The cell bodies are in the ganglion cell layer 
in the inner aspect of the retina. The eye is fully developed at 34 weeks gestation. 
The whole of the capsule of the lens is a basement membrane structure laid down 
by the lens epithelial cells and is transparent during life. After cataract surgery the 
equatorial cells (‘e’-cells), which provide normal slow growth of the lens, may 
proliferate and spread across the posterior capsule causing opacity and visual 
impairment requiring a further procedure. 
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FIGURE 7 – Microscopic lens fibre anatomy(Pandey et al., 2006) 
 
 
Figure 7. Lens fibres are originally ectoderemal cells which have become 
elongated under the influence of natural growth factors. The nuclei align under the 
anterior capsule where they obstruct light less than if they were posterior. All the 
fibres are of the same diameter and spacing thus reducing light scatter improving 
acuity.  
The lens grows slightly through life by mitosis of the ‘e’ cells at the equator. Not 
all of these cells can be removed at operation and they may continue to proliferate 
in a random fashion causing opacity on the remaining posterior capsule. This will 
reduce the post operative best corrected visual acuity and require further surgery to 
improve vision again. 
As with cataract, there is no effective medical treatment for reducing or preventing 
posterior capsule opacification although many have been tried. 
In industrialised countries, Nd:YAG laser is available to clear this opacity, but 
many millions of persons throughout the world have no access to this cure and the 
visual benefit of surgery may be indeed temporary. This means that cataract 
surgery in less developed countries earns an unwarranted bad name for long term 
effectiveness and may discourage other poor persons from seeking a cure. Taking 
Nd:YAG lasers to remote sites is not currently feasible because of electro-
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mechanical problems, especially variable electricity supplies and heavy, short 
charge batteries.(Gillies, 1998) 
Although surgical correction by incision of the posterior capsule is available to 
these persons, the numbers become overwhelming and the effort would be better 
directed towards new cataract surgeries for the (perhaps 25+) millions in poor 
circumstances, who currently require but have no access to treatment. For example, 
it is estimated that for the hundreds of millions of persons who live in Bangladesh 
there are only about twenty-eight ophthalmic surgeons active full time. If they did 
not have to deal with PCO they would, like everybody else, be vastly more 
effective.  
Currently the cost of cataract surgery in underdeveloped and remote areas is borne 
partly by governments with restricted budgets. Significant contribution comes from 
individual volunteer surgeons who initiate the surgical trips in coordination with 
the local surgeons, by charities, by equipment companies, by drug companies and 
by private organizations that provide manpower and money and equipment aided 
by local volunteers and patients’ family. Those locals who can contribute to the 
cost are helping to subsidise the poor. For example, in the city of Lumbini in Nepal 
(the birthplace of Buddha) the cost is US$35 maximum if it is affordable but no 
one is turned away according to the Royal Australian and New Zealand College of 
Ophthalmologists’ Newsletter June 2007. 
Since the world health organisation has assessed that cataract surgery is the cost 
effective way of dealing with cataract problems, perfecting it would increase its 
cost effectiveness even more.(Baltussen et al., 2004, Riaz et al., 2006) 
Even in sophisticated countries the cost of treatment of PCO is significant. 
Nd:YAG laser treatment of posterior capsule opacification is the next most 
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common claim to cataract surgery on Medicare in the USA.(Apple et al., 1992, Emery, 1999) 
Australian Medicare figures for 2006 are AU$1million (approx) compared with 
AU$8.8million (approx) for cataract surgery. The trends are in Figures 2&3. 
Nd:YAG laser does have a very small but well documented incidence of 
complications (see later) and should not be a routine procedure. Analyses of the 
effectiveness of measures to reduce PCO are delayed because the opacity usually 
takes years to become visually significant. It is much more common in paediatric 
surgery and less so in the very aged. It is very important to identify PCO early in 
children to prevent irreversible amblyopia in that eye.(Survey of Ophthalmology Editors, 2000) 
For the purposes of this thesis, symptomatic visual impairment was taken as the 
end point indication for capsulotomy. This can be criticised because it is subjective 
but it is the current practice. 
Many objective assessments of PCO are under trial but there is no agreement on 
uniformity. Computer analysis of digital retro illumination photographs is valid 
and reliable (Aslam, 2005, Aslam, 2006) but the most promising is the use of optical 
coherence tomography (OCT-1) which can measure thickness of the opacity and 
capsule thickness down to 10 microns.(Moreno-Montanes et al., 2005) This could standardise 
accurately assessment of PCO rates if widely available when used in conjunction 
with visual acuity, contrast sensitivity and spatial discrimination. It will allow 
standardised measurement of area, density and site so that prevention measures can 
be accurately evaluated against a background of changes in lens design and 
surgical technique. Unfortunately this examination is expensive and not readily 
accessible outside large centres. 
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CONCLUSION 
Of the many millions of IOL implants performed around the world every day, a 
PCO incidence of even 5% still represents considerable cost and functional 
impairment (see causes and prevention below) so that any incremental 
improvement in surgical performance is worthwhile. It would permit successful 
expansion of IOL surgery in underdeveloped communities since Nd:YAG laser is 
not widely available and takes up valuable time and resources when it is.  
The cost of posterior capsulotomy is considerable in any country when gauged 
against the local currency. When the time and resources needed is added to the 
time and opportunity lost in performing primary cataract surgery the problem is 
much greater than it first appears. This is not to say that capsulotomy should be 
abandoned for it returns the patient to independence and production. The aim 
should be to improve primary prevention. 
Even a mild degree of PCO can reduce visual efficiency especially of multifocal 
and accommodating IOLs, reducing sensitivity of the macula and limiting the 
patient’s performance in their environment. 
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CHAPTER FOUR 
Causes and prevention of posterior capsule 
opacification  
Posterior capsule opacification (PCO) is becoming less common after lens surgery 
and is effectively treated by laser.  
MECHANISMS  
Extracapsular cataract extraction (ECCE) with posterior chamber intraocular lens 
(IOL) implantation is the preferred surgical technique for the treatment of cataract 
whether in developed or developing countries. The Hollows Foundation is famous 
for its work in this latter area but many other organizations also work to provide 
low cost intraocular lenses, training of local surgeons and develop an effective 
technique not requiring sophisticated technology.  
Leaving the posterior capsule intact improves safety of cataract operation but may 
result in its opacification requiring further surgery and therefore any technique that 
can reduce this incidence and allow surgeons to perform more primary surgeries is 
worthwhile. The Cochrane Collaboration has published a protocol and analysis for 
“interventions for preventing posterior capsule opacification”.(Findl et al., 2007, Riaz et al., 
2006) 
That the capsular bag can survive long term without functioning lens epithelial 
cells was shown in a well constructed study of 100 cadaver pseudophakic eyes. 
The reason was unable to be explained. Thus the possibility of long term stability 
of the IOL and capsular integrity is assured. (Kleinmann et al., 2006)  
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At the completion of the current surgical technique of phacoemulsification and 
intraocular lens implant (IOL), there is very little inflammatory response and 
inflammatory cells are not a feature of the postoperative course or of PCO. If the 
eye had been the subject of previous trauma or inflammation resulting in 
intraocular fibrosis, then inflammatory cells may be important in the initiation of 
PCO. This can be interpreted as a wound healing response.(Bertelmann and Kojetinsky, 2001) 
This means that the posterior capsule, a basement membrane structure which 
remains clear throughout life, does not itself go opaque. The cells spreading onto 
its anterior surface behind the intraocular lens may cause visually significant 
opacity. This ingrowth may also be seen as a membrane between twin implanted 
(“piggy back”) IOLs. Despite the nicety of the distinction of the site of the opacity, 
the term posterior capsule opacification is universally used for this condition and is 
continued here. 
Clinically, PCO (also called secondary cataract) is subdivided into regeneratory or 
fibrotic with the former being the more common. Both cause opacity that can 
interfere significantly with vision if there is progress over time. Fibrotic PCO is 
randomly arranged and scatters the light causing symptoms as opposed to the 
orderly arrangement of fibres in the natural lens (Figure 7). “Posterior capsule 
thickness was a factor in reduction in best corrected visual acuity” as judged by 
optical coherence tomography (OCT-1).(Moreno-Montanes et al., 2008) 
Regeneratory PCO is a result of lens epithelial equatorial (‘e’ cells) migrating onto 
the posterior capsule behind the intraocular lens. These are either remnants of 
cortical cells left on the capsule during surgery or proliferation of equatorial cells 
which have not been able to be removed. They may be transitory clearing within 8 
weeks. They are sometimes referred to as “bladder” or “Wedl” cells and were 
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described originally more than a hundred years ago when they were referred to by 
eponymous name of Elschnig’s pearls.(Parsons, 1964) 
Fibrotic PCO occurs when anterior capsule cells (‘a’ cells) undergo transformation 
into myofibroblasts and cause fibrosis and contraction of the capsular bag or of the 
capsulorhexis. ‘E’ and ‘a’ cells both come from one continuous cell line but ‘a’ 
cells tend to stay anterior and ‘e’ cells tend to migrate across the posterior 
capsule(Marcantonio and Vrensen, 1999) unless prevented by lens design (see 
below).(Schmidbauer et al., 2001, Apple et al., 2001) 
It would seem logical that any attempt to remove as many epithelial cells as 
possible from the capsule during surgery would reduce posterior capsule 
opacification and aggressive polishing of the anterior and posterior capsule has 
been recommended by many authors over many years. The problem is that the 
removal of equatorial cells is technically the most difficult and dangerous part of 
the procedure. In a study of 194 uneventful cataract surgeries of various densities 
the authors concluded that “the results indicate that aggressive polishing of 
peripheral or adherent residual capsular opacity is not advisable as only five eyes 
with central residual opacity developed significant visible PCO”.(Mootha et al., 2004) 
Similarly, after polishing the posterior capsule of 200 consecutive patients, the 
incidence of PCO still rose to 50% at three years.(Wilhelmus and Emery, 1980) 
Conflicting results of the benefit of anterior capsule polishing in 130 silicon IOL 
implants in a randomised masked trial led to the conclusion that “this trend did not 
reach statistical significance”.(Bolz et al., 2006) 
Opacity and slight contraction of the anterior capsule (like a purse string) may in 
fact have some beneficial effect by increasing the posterior capsular bend at the 
posterior peripheral edge of the intraocular lens, tightening the posterior capsule 
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against the posterior surface of the lens and thus mechanically preventing in 
growth of any sort of cell between the lens and the capsule (the “shrink wrap 
effect”).(Dewey, 2006)  
Sommering’s ring is an almost universal finding in post mortem eyes with 
intraocular lenses and consists of cells trapped between the anterior and posterior 
capsules peripheral to the intraocular lens in a doughnut fashion. It is not 
particularly important visually while it remains contained and peripheral which is 
the majority of the time.(Apple et al., 1992, Schmidbauer et al., 2001)  
Even if the posterior capsule remains clear, asymmetrical fibrosis peripheral to the 
intraocular lens may result in wrinkling of the capsule which may slightly reduce 
the visual acuity but does not always require intervention.(Marcantonio et al., 2000) 
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FIGURE 8 – SOMMERING’S RING FROM BEHIND – 
MIYAKE-APPLE IMAGE (Pandey et al., 2006) 
 
 
Figure 8. Miyake–Apple images are obtained by sectioning a post mortem fixed 
eye through the equator. The anterior half is then set on an optically correct glass 
plate and photographed/videoed from behind. 
This image shows the doughnut of residual proliferated lens cells outside the IOL 
and behind the iris with a clear visual axis. Visual acuity probably was not affected 
in this patient. 
Edge of the IOL 
Sommering’s ring 
Ciliary body 
from behind 
Pupil 
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Technical features that are proven to reduce posterior capsule opacity have been 
identified as: (Apple et al., 2001, Pandey et al., 2004, Pandey et al., 2006) 
1 Cortical cleaving hydrodissection; 
2  Careful cortical clean-up;  
3 In-the-bag placement and fixation of the intraocular lens;  
4 Central anterior capsulorhexis of slightly smaller diameter than the 
intraocular lens;  
5 A lens material that is biocompatible;  
6 Maximum contact between the posterior capsule and intraocular lens; 
7  A square posterior truncated edge on the intraocular lens where it contacts 
the capsule.(Apple et al., 2000, Apple et al., 2001, Pandey et al., 2006, Pandey et al., 2004, Nishi et al., 
2004a) 
8 Maximum capsular bend at the posterior edge of the IOL with 360 degree 
barrier.(Dewey, 2006, Nishi et al., 2007) this is called the “shrink wrap effect”. 
9 Rotation of the hydrodissected nucleus of the lens three times before 
removal.(Vasavada et al., 2005)  
10 A second hydrodissection before irrigation/aspiration of the cortex.(Dewey, 2006)  
Items 7and 8 appear to be the most important.(Nishi et al., 2004b) 
Ultraviolet-A irradiation of the capsule at the time of surgery to remove lens 
epithelial cells (dose not specified) is an innovative approach recently reported 
(p=0.17) in a comparative study of 30 eyes.(Rajeev, 2007) This concept needs larger 
series to consolidate efficacy and safety.  
Routine posterior optic buttonholing in a primary posterior capsulorhexis for 
eradication of PCO in adults was reported in 500 intraocular lens implants with a 
low complication rate of 1% associated with the technique and no increase in 
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cystoid macular oedema post operatively. This technique has been used for a long 
time in paediatric IOL implants where PCO may still exceed 50%.(Mammalis, 2006, 
Menapeace, 2006)  
Systemic diseases appear to have little effect on posterior capsule opacification 
even though diabetes mellitis and steroid treatment, both local and systemic, are 
associated with posterior subcapsular opacities prior to surgery. These opacities 
usually come free of the capsule during surgery and do not often contribute to 
PCO. Diabetes was found not to be a factor in PCO in a study of 434 human eyes 
undergoing routine cataract surgery and intraocular lens implant.(Mian et al., 2005) 
Pseudoexfoliation (PXF) of the lens capsule has been anecdotally noted to increase 
the fragility of the capsule but also increase the fibrosis post operatively. But a 
study comparing 800 eyes with PXF against 1600 patients without showed that, 
using phacoemulsification, results can be obtained similar to routine 
surgeries.(Aldinci et al., 2008) 
Biochemical studies have shown that the lens epithelial cells involved in the PCO 
may change their protein matrix to smooth muscle in the form of actin thus 
representing a mesenchymal transition (see above). Cytokines, especially 
transforming growth factor-beta (TGF-beta), are thought to be involved in this 
metamorphosis from studies of donor human eyes.(Marcantonio and Vrensen, 1999, Marcantonio et 
al., 2000, McAvoy et al., 2000) Normally occurring fibroblast growth factor (FGF) and 
transforming growth factor-beta (TGF-beta) play important roles influencing the 
lens epithelial cell behaviour and persist in the capsular bag after surgery.(Marcantonio 
et al., 2000) 
 
36 
FIGURE 9 – EFFECT OF GROWTH FACTORS ON LENS 
EPITHELIAL CELLS. (McAvoy et al., 2000) 
 
Figure 9. Diagram illustrating the proposed roles played by fibroblast growth factor 
(fgf) and transforming growth factor (tgf-β) in modulating the lens cell phenotype. 
Fibroblast growth factor initiates and promotes fibre differentiation but tgf-β is also 
required for fibre maturation and/or survival. In contrast to its normal role in fibre 
differentiation, tgf-β induces lens epithelial cells to form fibrotic plaques and 
disrupts normal cellular architecture. 
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An interesting experiment confirming the importance of growth factors on lens 
epithelial cells was performed by culturing human epithelial cells in vitro from post 
mortem eyes. The mitotic activity returned at a rate comparable to that of intact 
cultured non-cataractous lenses showing that the potential for proliferation persists 
for a very long time after surgery.(Rakic et al., 2000) 
FGF has 3 receptor genes in lens epithelial cells and is important for ensuring that 
normal lens cell polarity is maintained as the new fibres continue to differentiate 
throughout life and maintain the ordered cellular architecture responsible for 
transparency of the normal human lens. FGF has a higher concentration in vitreous 
than aqueous. Explanted lens cells exposed to vitreous lose organelles and assume 
the characteristics of lens fibres but not when exposed to aqueous. It is logical to 
imply that FGF in persisting lens cells continues to enable them to differentiate and 
proliferate.  
TGF-beta is a family of factors present in the eye that can induce apoptotic cell 
death and localised capsule wrinkling. These have been identified in subcapsular 
cataracts and posterior capsule opacification. Transgenic studies have shown that 
TGF-beta can induce cataract and the epithelial-mesenchymal transition that is 
seen in fibrotic PCO. Thus, in general, FGF is good and TGF-beta is bad for 
normal lens clarity.(McAvoy et al., 2000) 
The mechanism of regulation of these families of factors in vivo, their 
bioavailability and mediation is not known but “will be fundamental to   
understanding the molecular basis of cataract”.(McAvoy et al., 2000) 
Detailed analysis of these factors is beyond the scope of this paper. An extensive 
review of the research into these factors can be found in the Peter Bishop Lecture 
of 2000.(McAvoy et al., 2000) and good reviews of the pathophysiology of posterior 
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capsule opacification are found in Apple, Clarke, Bertelmann, de Longh, Pandey, 
Wormstone, and Survey of Ophthalmology supplement no 1.(Apple et al., 1992, Survey of 
Ophthalmology Editors, 2000, Clark, 2000, Bertelmann and Kojetinsky, 2001, Pandey et al., 2006, Wormstone, 2002) (de 
Longh et al., 2005) 
The incidence of clinically significant PCO was conservatively quoted as 25% in 
1998 and 7.5% in 2005 at twenty-four months over a variety of IOL materials. 
(Figure 4) some materials and lens designs performed better over time than others 
especially those with “sharp” posterior edges to the optic.(Schmidbauer et al., 2001, 
Schaumberg et al., 1998, McLeod, 2005, Nishi et al., 2007)  This improvement is reported in many 
other papers and is attributed to the factors listed above being improved and 
implemented worldwide.(Pandey et al., 2006) 
With new techniques and lens design including accommodating and multi focal 
intraocular lenses, refractive surgery involving the lens and presbyopia surgery, the 
permanent clarity of the posterior capsule becomes paramount and integral for the 
success of the operation and PCO must be eliminated.(Dewey, 2006)  
TREATMENT OF POSTERIOR CAPSULE OPACIFICATION 
 MEDICAL  
There is no universally accepted medical treatment for the prevention of cataract or 
PCO. It is appropriate to review briefly published measures that have been tried in 
vivo, in vitro and ex vivo. (see chapter 5) 
N-acetylcarnosine drops have been claimed to be effective particularly by 
investigators in Europe using mainly animal in vivo trials. The drug is on sale in 
Europe and apparently extensively used by the public. (Personal Communication Milverton 
2006) N-acetylcarnosine 1% was studied in a clinical trial of 26 cataract patients 
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compared to 13 placebo and 10 untreated. The treated group had two drops twice a 
day for six months without surgery. Stereocinematographic image and 
retroilllummation photography were used to assess the results as well as corrected 
visual acuity. Ninety percent showed a gradual improvement in acuity, glare 
sensitivity and less density in the patients who had posterior subcapsular cataracts. 
An extension of the study to 24 months claimed that the effect is sustainable. The 
mechanism of action is unknown but is thought to be an antioxidant.(Babizhayev, 2001) 
L-carnosine is a related natural peptide containing histidine and similar results are 
claimed but not well documented. 
Gene therapy is in its infancy and the appropriate target genes are being researched 
using proapoptotic molecule manipulation.(Malecase, 2006) 
Lens regeneration is a concept which is unlikely to be feasible in the foreseeable 
future.(Gwon, 2006, Gwon et al., 1993)  
Immunotoxin MDX-RA is in extended human trials (see below). 
 SURGICAL 
Despite the eight proven items and two new techniques listed above reducing the 
incidence of PCO, it has not been eliminated. Creating an opening in the opacity of 
the capsule requires either surgical needling or laser. The former is another 
penetration of the globe with the small risk of infection but requires no 
sophisticated equipment; the latter is elegant, safe and expensive but not suitable 
for remote locations.  
Nd:YAG laser ablation (393 nm) of the posterior capsule is accepted as the best 
form of treatment of PCO. It acts by photo disruption using acoustic shock waves 
generated by ionisation and plasma formation to cut the opacity without the need 
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for pigment absorption and producing carbon dioxide and water. The physics of 
these reactions is discussed in detail by Puliafito and Steinert.(Puliafito and Steinert, 1984) 
This treatment is indicated when the opacity affects the best corrected visual acuity 
and is symptomatic. It may take five years (rarely more) to be clinically significant 
but more commonly this occurs at around two to three years. “Patients with PCO 
seemed to have more disturbed visual function than cataract patients with the same 
visual acuity” and request treatment sooner.(Sundelin et al., 2006, Sundelin and Sjostrand, 1999) 
In 1996, when the incidence of PCO was around 43% (Figure 4), it was estimated 
that 9% of the surgically treated population still had clinically significant untreated 
PCO 5 years post operation.(Sundelin and Sjostrand, 1999) this delay skewed incidence 
Figures based on Nd:YAG treatments but other objective criteria were not 
available. The incidence of Nd:YAG capsulotomy post operatively is falling 
worldwide but it is higher in children and lower in old age.(Maltzman, 1989) these 
Figures are confirmed by Medicare Australia statistics 2006. (Figures 1 and 2) 
COMPLICATIONS OF ND:YAG LASER 
Nd:YAG laser is a very effective and successful technique and a second treatment 
is rarely necessary. It may damage the IOL or let it displace, raise intraocular 
pressure, precipitate cystoid macular oedema or retinal detachment, or exacerbate 
localised endophthalmitis. Fortunately, in experienced hands, these are very rare.  
The costs are still considerable; “1 million patients per year costs the USA health 
care system up to us$250 million annually”.(Schmidbauer et al., 2001) and Medicare 
Australia rebated AU$8,888,000 in 2006. 
A statistically significant increase (p=0.02) in the incidence of retinal detachment 
or retinal break was found in young white males by reviewing 57,103 randomly 
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selected USA Medicare beneficiaries covering the years 1986-1987; 337 retinal 
detachments and 194 retinal breaks were found. This is a small incidence but 
possibly a lifelong problem.(Javitt et al., 1992) Similar results were found for both 
diabetic and non-diabetic patients (n = 806) confirming that diabetes mellitus is not 
a factor in retinal detachment after Nd:YAG laser.(Elgohary and Dowler, 2006)  
CONCLUSION.  
The incidence of PCO after cataract surgery is still falling worldwide to less than 
5%. Improved surgical techniques, better IOL designs and more biocompatible lens 
materials have all combined synergistically to reduce the incidence over time. 
Pharmacological attempts to reduce PCO are still rudimentary. 
Nd:YAG laser obliteration of PCO is very effective and safe when reserved for 
patients with symptomatic loss of best corrected postoperative visual acuity. 
Polishing of the capsule prior to implantation is not worth the risk and time. 
Surgical treatments such as needling of the capsule or primary buttonholing may 
have a place in specific cases. 
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CHAPTER FIVE 
         Pharmacological attempts to reduce posterior capsule 
opacification  
Experiments using Xylocaine (lidocaine) will be detailed in a separate chapter.  
Experiments to find a substance which would reduce PCO go back to the early 
1970s when many substances were rejected because they were too toxic to the corneal 
endothelium. Table 1 lists most of the substances which have been used 
experimentally. Carbachol(Birnbaum et al., 1987) and acetylcholine(Hull, 1979), which have been 
used intraocularly for many years to constrict the pupil, were cleared of toxic effect to 
the corneal endothelium and do not increase PCO rates as judged by Nd:YAG laser 
rates.(West, 2007) Xylocaine 1% 1 mL unpreserved is the drug most commonly injected 
into the anterior chamber without toxic effect on the corneal endothelium (see later). 
Adrenalin is often used in the infusion fluid and occasionally in small dose into the 
anterior chamber to help keep the pupil dilated and has no measured effect on the 
corneal endothelium in the concentrations used clinically.(Hull, 1979) 
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TABLE 1 – SOME SUBSTANCES USED IN ATTEMPTS TO 
REDUCE PCO 
CYTOTOXIC 5 fluorouracil (5FU) 
Mitomycin c (MMC) 
Saporin 
Daunorubicin 
Calcimycin 
Methotrexate 
Colchicine 
Cyclosporin A 
NSAIDS Indomethacin 
Diclofenac 
Refcoxib 
Celecoxib 
OSMOTIC AGENTS Distilled/deionised water (H20) 
Hypertonic saline (NaCl) 
IMMUNOLOGIC Immunotoxin MDX-RA 
Immunotoxin 4197x-ricin 
Gene therapies 
STEROIDS Dexamethasone 
CALCIUM ANTAGONISTS Ethylenediaminetetraacetic acid (EDTA) 
DETERGENTS/DISINTEGRINS Triton X100 
Salmosin 
PHOTOTHERAPY Ultraviolet-A (UVA) 
LOCAL ANAESTHETICS Lidocaine 
Proparacaine 
Cocaine 
Bupivacaine 
Ropivacaine 
MISCELLANEOUS Heparin 
Retinoic acid 
RGD peptide (arginine glycine asparticacid 
sequence) 
L-carnosine 
N-acetylcarnosine 
Tranilast 
Calcimycin 
Antioxidant vitamins 
 
Note 
Some substances have more than one action and could be reclassified in this Table 
44 
 
ANIMAL EXPERIMENTS  
IN VITRO 
The validity of using rabbit eyes as a model for studies to elucidate human PCO 
was assessed in a series of experiments analysing postoperative slit lamp examination 
and aqueous humour analysis. “The study showed that the same components that are 
reported in human PCO are also components of PCO in the rabbit” but that they 
develop much more rapidly e.g. 2 months as opposed to 2 years.(Wallentin, 2002)  
The pH tolerance of both rabbit and human corneal endothelial cells was tested 
using a dual chambered specular microscope over the range of pH 3.5 to 10.0. It was 
concluded that outside the range of 6.5 to 8.5 structural and perhaps functional 
changes start to occur in the cells after three hours perfusion compared with balanced 
salt as control. As few cataract surgeries last three hours (less than thirty minutes is 
more likely) a slight extension of the pH range over a shorter time was thought to be 
possibly acceptable.(Gonnering, 1979) 
The osmotic tolerance of both rabbit and human corneal endothelium was tested on 
excised corneae mounted in a specular microscope. They were perfused with balanced 
salt solutions of varying osmolality from 192 to 498 milliosmoles per litre (mOsm/L) 
at 37°c and l5 mmHg for 15 minutes then fixed and studied by transmission electron 
microscopy; 300 mOsm/L was taken as “normal” for the purposes of the experiment. 
The conclusion was that “the corneal endothelium can tolerate a wide range of 
solution osmolalities (200 to 400) without marked endothelial cell breakdown if the 
essential ions are present”.(Edelhauser, 1981)  
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The effect of commercially available eye drops which may be washed into the eye 
during surgery was assessed using rabbit corneae perfused for five minutes. 
Epinephrine (adrenalin) 1/1000 was toxic to corneal endothelium but a five fold 
dilution showed no change in the cells. This is important because epinephrine may be 
combined with other drugs in fixed ratios in commercial preparations of eye drops. 
Preservatives such as benzalkonium chloride 0.01% (a cationic surfactant), and 
Chlorhexidine are toxic to corneal endothelial cells in rabbits in the bacteriostatic 
concentrations currently in use and therefore should never be used in intraocular 
surgery.(Eleftheriadis et al., 2002)  Special care must be taken in the operating theatre to keep 
antiseptic preparations separate from solutions used for intraocular use. 
Carbachol (carbamyl choline) 0.01% which may be used to contract the pupil at the 
end of the surgery causes transient corneal swelling and this may be due to the 
relatively low pH of 5.2 of older preparations.(Hull, 1979) newer preparations have a 
pH of 6.95.(Birnbaum et al., 1987) Acetylcholine 1% is used for the same purpose. It is 
reconstituted with 5% mannitol giving a pH of 7.1. Although the osmolality is high at 
430 mOsm/l there is little change in the corneal endothelium in rabbits as assessed by 
scanning and transmission electron microscopy.(Hull, 1979) 
Calcimycin (a calcium ion antibiotic ionophore) was tested against human and rabbit 
endothelial cells suspended in foetal calf serum. The drug produced apoptosis and it 
was found that it was toxic to the cells after thirty minutes exposure. The author of the 
study concluded that induction of apoptosis was a possible treatment mechanism for 
preventing posterior capsule opacification but required further experimentation.(Geissler, 
2001) There have been no further reports found.  
Salmosin, a disintegrin, was tested ex vivo on the excised anterior capsule lens 
epithelial cells of both rabbit and human eyes. Adhesion and migration and 
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proliferation were all inhibited but not as much as it was in an in vivo experiment with 
rabbit eyes.(Kim, 2002) 
Local anaesthetic eye drops of bupivacaine 0.75%, unpreserved, lidocaine HCl 0.5% 
and tetracaine HCl 0.5% are commercially available. Tested in 72 rabbits by anterior 
chamber infusion, all showed corneal thickening and opacification, the least so with 
tetracaine.(Judge et al., 1998) They must not be used intraocularly. 
The effect of intraocular lens materials (as opposed to design) was tested against 
bovine lens epithelial cells cultured for one month. Polymethylmethacrylate 
(PMMA), silicone and hydrophobic acrylic lenses were treated with a gas plasma to 
modify the surface characteristics of the material. This increased the surface 
hydrophilicity and prevented the lens epithelial cells from converting to the 
characteristic fibroblast phenotype of the cells found in posterior capsule 
opacification. It was suggested that this relatively simple method would reduce PCO 
in human lens surgery.(Yuen et al., 2006) To date there is no report of this being available 
commercially. 
 Heparin was used as a coating for intraocular lenses about 12 years ago by the 
Pharmacia Company but is not currently available. 
5-fluorouracil (5FU) is an antimetabolite with antifibrotic properties used in 
glaucoma surgery to prevent closure of the filter created. In the cell it is converted 
into active metabolites that interfere with the metabolism of DNA and RNA. Forty-
six sheep corneae were exposed to 5FU concentrations varying from 0.0l mg/mL to 
10.0 mg/mL for four hours at room temperature and compared with saline as a 
positive control and chlorhexidine gluconate as a negative (toxic) control. Up to a 
concentration of 1.0 mg/mL, 5FU showed no difference from the corneal buttons 
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exposed to normal saline.(Mannis et al., 1988) There is a dearth of documentation in the 
literature of toxicity to the cornea of 5FU 50 mg/mL used during glaucoma surgery 
suggesting that it is safe in the concentrations used. Corneal micro ulcers from 5FU 
spilled during subconjunctival injection after glaucoma surgery are well known and 
are transient. 
IN summary, many chemicals are toxic to lens epithelial cells and may mediate their 
effect by apoptosis, disintegration or change in adherence or combinations of these. 
Many are also toxic to the corneal endothelium and a compromise concentration is 
not always possible making them unsuitable for clinical use. 
IN VIVO 
5-fluorouracil (5FU) in a concentration of 50 mg/mL was compared against both 
distilled and deionised water and commercial balanced salt solution in a group of 34 
week old rabbits having clear lens extractions in both eyes. Randomly chosen one eye 
had the substances instilled using the “perfect capsule” (Milvella,Sydney, Australia) 
sealed capsular irrigation device. The post mortem histology showed significant 
reduction in posterior capsule opacification in the 5FU group (p=0.0039).(Abdelwahab et 
al., 2006) 
5FU in a sustained release (0.2 microgram/hr) intracapsular ring was studied in six 
rabbit eyes undergoing phacoemulsification. Transmission electron microscopy eight 
weeks after surgery showed that the potential effects anticipated were not 
demonstrated but there was no toxicity to intraocular structures.(Pandey et al., 2002) No 
reference to other concentrations was found. 
Mitomycin-c (MMC) inhibits DNA synthesis. 0.2 mg/mL dissolved in sodium 
hyaluronate was compared with the same concentration in balanced salt solution 
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using 36 rabbit eyes. Three months after cataract surgery, visible light obstruction by 
PCO was halved in the first group.(Chung et al., 2000) 
5FU 12.5 mg/mL and MMC were compared in 12 rabbits having bilateral 
phacoemulsification. After four weeks these doses did not show significant inhibitory 
effect on after cataract (PCO) formation.(Chew et al., 2006) 
Colchicine, an anti inflammatory, inhibits cell division by interfering with the 
mitotic spindle. In a sustained drug delivery system from an intraocular lens studied 
after phacoemulsification in 34 rabbit eyes it was effective in reducing the mean PCO 
compared to control. The side effects were of an inflammatory anterior chamber 
reaction and corneal and retinal toxicity. The author suggested that an acceptable 
biocompatible dose may be determined by further investigation.(Legler et al., 1993)  
Daunorubicin, an early antimetabolic antibiotic used in some leukaemias, was 
encapsulated in liposomes in varying concentrations from 0.2 mg/mL to 
20 microg/mL. Rabbit eyes were studied after extracapsular extraction of the lens. 
Only a few lens epithelial cells remained in the bag eight weeks post operatively but 
corneal oedema and eosinophilic infiltration and loss of corneal endothelial cells 
resulted.(Wu, 2000)  
Daunorubicin 33microg was compared with indomethacin 715 microg in a sustained 
drug delivery system in 89 rabbit eyes after intraocular lens implant. Indomethacin is 
not an ideal drug because of its relative insolubility in the carrier. The daunorubicin 
reduced posterior capsular fibrosis by approximately 50% but produced a mild 
inflammation and some endothelial cell loss. The indomethacin group showed 
inflammation of the ciliary body.(Tetz et al., 1996, Tetz and Nimsgern, 1999) Neither drug has 
progressed to clinical use.  
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Cyclooxygenase-2 inhibition was tested using rofecoxib and celecoxib in canine 
cataracts ex vivo. This is the only positive result found for these substances and the 
authors suggested that “in vivo may be an effective technique in preventing 
PCO”.(Chandler et al., 2007) 
RGD peptide (arginine-glycine-aspartate acid sequence) was compared with 
ethylene diaminetetraaceticacid (EDTA) in an attempt to prevent cell migration and 
adhesion in five rabbit eyes after intraocular lens implant. This produced a 
“significant inhibition”. (Nishi et al., 1997b)  No further follow up of this substance can be 
found.  
Retinoic acid 250 μg/mL and mitomycin-C 0.04 mg/mL were injected into the 
capsular bag of 27 rabbit eyes after phacoemulsification. Both reduced the incidence 
of PCO as compared to controls. Two eyes in the mitomycin group had corneal 
oedema with the author concluding “the optimum biocompatible dose must be 
carefully determined by further investigation”.(Inan et al., 2001a) 
Mitomycin-C and distilled water were compared in sealed capsule irrigation in 
24 rabbit eyes assessed at three months. MMC had statistically less PCO.(Kim et al., 2007) 
The same group of authors then explored different substances using the same 
techniques in rabbit eyes. Dexamethasone 4 mg/mL had a very weak effect on 
preventing posterior capsule opacification and diclofenac had some effect. EDTA, 
EDTA+ RGD peptide and mitomycin-C “significantly prevented the development of 
posterior capsule opacification in the rabbit eye”.(Inan et al., 2001b) 
Mitomycin-C 0.2 mg/mL in the viscoelastic sodium hyaluronate in 6 rabbit eyes 
reduced PCO compared with placebos without toxic effects to the eye.(Chung et al., 2000) 
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Comparison of a number of substances in rabbit eyes in a small study showed that 
distilled water and EDTA 10 mg/mL were the most efficient in retarding the 
appearance of PCO. It was noted that 5FU 33 mg/mL still prevented anterior capsular 
opacification. This concentration is less than the 50 mg/mL used in other experiments. 
The study also found that distilled water reduced the appearance of PCO but not as 
much as 5FU.(Fernandez et al., 2004) 
Demineralised water was compared with Triton X-l00 (a detergent) in the sealed 
capsule irrigation device in four rabbit eyes compared with the same substances 
without the sealed capsular irrigation. Histological examination of the enucleated eyes 
immediately after surgery showed that there was no collateral damage in the sealed 
capsular group. In the triton-x group there was significant damage to the eye, even 
though there was complete destruction of lens epithelial cells, when the sealed 
capsular device was not used.(Maloof et al., 2005) 
The antimitotics 5FU (12.5 mg/mL) and MMC 0.l mg/mL were compared in twelve 
rabbits having bilateral phacoemulsification. After four weeks it was found that these 
low doses did not show a significant inhibitory effect on after cataract formation.(Chew 
et al., 2006) 
Saporin, a cytotoxic, was conjugated with polylysine because that substance binds to 
lens capsule membranes but not surrounding tissues. Of nine rabbit eyes followed for 
forty weeks, six showed a delay of cortical regrowth approximately two to three times 
that of control eyes. The proposition was that a conjugate of substances may be more 
effective than saporin alone.(Bretton et al., 1999)  
Inflating an endocapsular balloon following cataract extraction was a novel 
approach trying to avoid drug toxicity in fifteen rabbits and thirteen primates followed 
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four to thirty two months after surgery. “filling of the capsule tautly and removing the 
lens epithelial cells effectively reduced capsular opacification but did not completely 
inhibit lens epithelial cell migration”.(Nishi et al., 1997a)  
Gene therapy to induce apoptosis in aspirated rabbit and human lens epithelial cells 
was explored using several proapoptotic molecules. Some were effective and further 
research on this novel approach was suggested.(Malecase, 2006)  
Heparin is a mucopolysaccharide that occurs in mammalian tissues. It inhibits the 
formation of a stable fibrin clot. Heparin in an intraocular drug delivery system was 
compared with 5% drops in 50 rabbits and achieved a higher aqueous humour level 
for longer. “The findings indicate potential prevention of PCO with minimum toxic 
and side effects”.(Xie et al., 2003) 
Tranilast, n-(3,4-dimethoxycinnamoyl)-anthranillic acid, was introduced as an 
antiallergic drug acting as a mast cell stabiliser and antihistamine. Subsequently it 
was found to have antifibrotic effect both by inhibition of fibroblast proliferation and 
also transformation into myofibroblasts thus reducing collagen formation. It also 
inhibits, prostaglandin e2, vascular endothelial growth factor VEGF and transforming 
growth factor TGF-beta. Tranilast has low bioavailability as eye drops (5%) and short 
life so a comparison of 0.15mg free tfree and bound in microspheres (tmicro) was 
injected into the capsule after phacoemulsification without IOL in 37 rabbits. A 
severe anterior chamber exudation was noted in all animals but not histological 
evidence of tissue damage was seen. In the animals with the sustained release 
preparation, reduced PCO was noted for up to 3 months. The mode of action may be 
by inhibiting TGF-beta. Because the eye drop form has been available commercially 
in Japan without toxic effects, the authors felt “further studies are needed to determine 
the lowest effective concentration and the long-term safety profile”.(Wang et al., 2007) 
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Immunotoxin 4197x-ricin a “inhibits protein synthesis and human epithelial cell 
proliferation on the inner surface of the posterior capsule”.(Tarsio, Kelleher et al 1997) Human 
lens epithelial cells cultured in vitro on their original lens capsules were almost 
completely inhibited at relatively low concentrations and the effect lasted up to 3 
weeks after withdrawal of the immunotoxin and several media exchanges.(Tarsio et al., 
1997) 
In summary, in vivo animal experiments suggest that currently the most effective 
and least toxic chemical appears to be 5FU used with a sealed capsular irrigation 
device. The safe effective dose without sealed capsule is not yet determined but 
appears to lie between 12.5 and 50 mg/mL. 
 HUMAN EXPERIMENTS 
The most interesting and specific approach to reducing PCO is by immunotoxins. 
Immunotoxin (MDX-RA) specific for lens epithelial cells, assessed in a trial of 42 
patients against 21 controls, the incidence of PCO was reduced (p=0.004) over a 
twenty four month follow up. Need for Nd:YAG laser was taken as the endpoint. This 
is now in larger clinical trials.(Spalton, 1999, Clark, 2000, Clark, 1998) 
Heparin eye drops post operatively was used in a case controlled study lasting four 
years. One hundred patients and 100 controls were followed for at least twenty four 
months with no complications in the control group. The incidence of fibrotic PCO 
requiring Nd:YAG was halved in the control group (p=0.15).(Mastropasqua, 1997) 
Demineralised water in conjunction with a sealed capsule device used for two 
minutes after phacoemulsification and implantation of one hydrophilic acrylic IOL 
was assessed in 17 patients. No side effects were noted compared with controls but “it 
is not possible to reduce PCO development significantly, thus alternative substances 
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should be evaluated”.(Rabsilber and I-J., 2006) This is in contrast to the in vitro experiment 
using excised human anterior capsule specimens.(Crowston et al., 2004) 
MMC  as used in glaucoma surgery is promptly toxic to the corneal endothelium if it 
inadvertently enters the eye in a concentration of 200-500 μg/mL but 20 μg/mL 
“appears non toxic” but perhaps not effective.(McDermott et al., 1994) 
Antioxidant vitamins orally have been used to try to reduce the incidence of cataract 
with conflicting conclusions.(Kuzniarz and al., 2001, Gritz et al., 2006) NO reliable report of their 
use to reduce PCO could be found. 
5FU is being trialed clinically using 50 mg/mL in the sealed capsule device. Short 
term results are optimistic but long term follow up is awaited. (Milverton, Personal 
Communication 2006). 
In conclusion, there is no pharmacologic preparartion currently available clinically 
for the prevention of PCO in routine cataract surgery. 
54 
CHAPTER SIX 
Xylocaine - properties and actions  
Xylocaine was chosen for this investigation because of its well known safety profile 
and its lesser known slight cytotoxicity. 
Xylocaine is lidocaine hydrochloride, formerly known in some markets as 
lignocaine. Marketed by the Astra-Zeneca (Sydney, Australia) company, it is the most 
commonly used drug injected into the eye. Chemically it is 2-diethylaminoaceto-2, 6-
xylidide. It is classified as a membrane stabilising agent and is a local anaesthetic of 
the amide type. It is extremely stable and can be sterilised by autoclaving. The safety 
of this compound for intraocular use in the form of Xylocaine unpreserved 1% 1mL 
has been confirmed both short and long term.  
Unpreserved Xylocaine solutions are sterile, isotonic and contain also sodium 
chloride, sodium hydroxide for pH adjustment (between 5 and 7) and water for 
injection. There is no specific antimicrobial agent. Therefore to prevent cross 
infection multiple dose containers must not be used. (Spalton, 2000) 
PHARMACOLOGY  
Lidocaine, like other local anaesthetics, causes a reversible blockade of nerve 
impulse propagation and is thought to act on the sodium channels of the nerve 
membrane. They all have effects on the peripheral sensory and motor nerves, brain 
and myocardium and have been used as therapy for these latter organs.  
PHARMACOKINETICS  
Lidocaine has rapid onset and medium duration of action compared to other local 
anaesthetics. Onset of less than five minutes after peripheral infiltration or injection in 
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the orbit is routine. The 1% concentration has less effect on motor than on sensory 
nerves. 
Plasma binding is dependent on drug concentration and decreases with increasing 
drug dose so that 60-80% is protein bound in whole blood. Lidocaine passes across 
the blood-brain and placental barriers by passive diffusion and therefore can diffuse 
into the brain and brain stem from the orbit in rare circumstances with potentially 
serious cerebral depression if not promptly recognised.  
Approximately 90% of a parenteral dose is rapidly metabolised by the liver by 
deethylation and less than 10% is excreted unchanged in urine. Metabolic products 
are active. (Product Information  eMIMS 2007) 
Injected into the anterior chamber, it is rapidly taken up by the ciliary body and iris, 
dilating the pupil. It is washed out unmetabolised with a half life of about nine 
minutes.(Anders, 1999) Traces of Xylocaine can be detected in the aqueous after retro and 
parabulbar block but no ocular or systemic toxicity has been recorded from these 
injections.(Salomon, 1990) 
ADVERSE REACTIONS 
Systemic toxicity has been recorded and begins with central nervous system 
depression followed, in high concentrations by bradycardia, hypotension and systemic 
collapse. This is more extensive if systemic absorption follows vascular penetration 
and in epidural administration where there may be concomitant sympathetic nerve 
block. Systemic reactions are rare and are generally dose-related to high plasma levels 
and rarely to hypersensitivity, idiosyncrasy or cardiac intolerance. Xylocaine is 
sometimes used intravenously in cardiac arrhythmias for its myocardial depressant 
effect. 
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Persistent extraocular muscle dysfunction may be due to direct trauma of the 
injection rather than chemical effect and is rare.  
Xylocaine 1% with adrenaline 1:100,000 (or less) may perhaps be safe for the 
corneal endothelium but studies are lacking. Its main disadvantage would be the low 
pH of 4.5 approximately which exceeds the pH tolerance of the endothelium(Gonnering, 
1979). 
CELL TOXICITY IN VITRO  
In common with other local anaesthetics in this group, lidocaine has some 
antibacterial and cell toxicity.(Mullin and Rubinfeld, 1997)  
Bacterial growth of common nosocomial organisms is also suppressed by various 
concentrations of lidocaine in a dose dependent fashion in vivo. Gram negative 
organisms were more sensitive than Staphylococcus aureus. The authors suggested 
that local anaesthesia “may have a role in the prophylaxis and, in the case of 
methicillin resistant and vancomycin resistant bacteria, the treatment of surgical 
wound infection”.(Parr et al., 1999) 
Concentrations of 1% and 2% lidocaine caused a significant decline in colony 
counts of E coli but not P aeruginosa and S epidermidis and slightly of S aureus but 
when in propofol, “did not exhibit adequate antibacterial activity to prevent infective 
complications”.(Labetoulle et al., 2002) In contrast, the opposite is claimed in another in vitro 
study!(Garaj et al., 1999) 
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Sodium bicarbonate (NaHCO3) when added to lidocaine to reduce the 
uncomfortable sensation of injection by raising the pH, enhanced the killing 
effect.(Thompson et al., 1993) 
             (Peck et al., 1985) with reduced cell respiration and dehydrogenase activity.(Fazly and Salt, 1983) 
Chinese hamster lung fibroblast cultures exposed up to 48 hours to varying 
concentrations of bupivacaine, procaine and lidocaine showed “local anaesthetic 
drugs produce major toxic effects on several cell functions, including cell division 
and survival”.(Sturrock and Nunn, 1979) Granulocyte phagocytosis activity was depressed by 
both lidocaine and bupivacaine in vitro. This does not help to explain their anti 
bacterial activity.(Kiefer et al., 2003) 
Murine macrophage cell production of nitric oxide was suppressed by lidocaine, 
suggesting a protective effect against this inflammatory mediator.(Shiga et al., 2001)  
Whether these antibacterial actions translate also to lower postoperative 
endophthalmitis rates is unknown and will take time to evaluate because of the 
inherent difficulty of assessing the already very low incidence of this complication.  
CELL TOXICITY IN ANIMALS  
Xylocaine 1% and 2% 0.l mL preservative free anterior chamber injections were 
compared in 16 healthy dogs. “no adverse ocular effects were observed after 
intracameral injection”.(Gerding, 2004) 
Lidocaine 10 mg or bupivacaine 5 mg was injected into the vitreous of 32 rabbits to 
determine retinal toxicity. The electroretinogram b-wave (which assessed the outer 
retina) was depressed for about four hours. Oscillatory potentials (assessing the inner 
retina) and visually evoked potentials (assessing the ganglion cells and nerve fibre 
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layer) were not depressed. Histological examination by light microscopy showed no 
damage. The authors concluded that these local anaesthetics were safe to the retina in 
the doses used clinically.(Zemel et al., 1995) The same results were recorded using 34 rabbits 
using intra-vitreal injections of lidocaine 2% 0.2 mL, and bupivacaine 0.75% and a 
1:1 mixture of the two.(Liang et al., 1998) 
Rabbit corneae were excised and the endothelium was exposed for 20 minutes to 
three concentrations of lidocaine in sodium hyaluronate, sodium hyaluronate alone, 
balanced salt, distilled water, mitomycin-c 0.02% or dextran 15%. Viscoanaesthetic 
solutions of lidocaine were safe to a concentration of 1.65%.(Trivedi et al., 2003) 
Porcine corneae (n=18) were exposed to lidocaine unpreserved concentrations of 
1%, 5% and 10% for 60 minutes. The 1% did not cause significantly more corneal 
endothelial cell toxicity than the controls, indicating that only the 1% should be used 
clinically. (Eggeling et al., 2000)  
Lidocaine 2% and bupivacaine 0.5% injected intra-camerally caused significant 
corneal thickening and opacity in rabbits. These concentrations are available 
commercially and “may be a potential risk factor for corneal endothelial injury”.(Guzey 
et al., 2002) 
Xylocaine 1% and 5% were applied to excised rabbit corneae for 20 minutes and 
then stained with trypan blue and alizarin red (which stain collagen). There was no 
staining but the “5% had more marked cell alterations”.(Werner et al., 1998) 
Lidocaine 4%, bupivacaine 0.75%, proparacaine 0 5% and tetracaine 0.5% were 
injected into the anterior chambers of rabbits at lens surgery. All produced corneal 
thickening and opacification, tetracaine being the least toxic. These are the 
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concentrations available commercially as eye drops and therefore should not enter the 
eye.(Judge et al., 1998) 
Electron microscopy of 8 rabbit corneae and irides after intracameral lidocaine 1% 
0.2 mL and phacoemulsification were compared with a control of 8 eyes. Even a short 
exposure of intracameral lidocaine to the ocular tissues can induce histological 
changes that may result in functional defects”.(Atilla et al., 2003) 
Lidocaine 1% was evaluated against balanced salt solution by exposing excised 
anterior capsule fragments for up to five minutes and then stained and analysed by 
photomicrographs. “Preservative free lidocaine 1% may help diminish the amount of 
live lens epithelial cells by facilitating cortical cleanup, by loosening the desmosomal 
area of cell adhesion with decreased cellular adherence or by direct toxic effect. The 
use of this agent may help prevent posterior capsule opacification”.(Vargas et al., 2003) 
Lidocaine 1% preservative free plus carbachol 0.01% 0.02 mL compared with 
normal saline in rabbits “did not produce morphological changes in the corneal 
endothelium” on scanning electron microscopy of the excised buttons after 
intracameral injection. The evaluation was at one week and at one month. (Liou et al., 2004)    
In conclusion, lidocaine in the form of Xylocaine unpreserved is not toxic to the 
cornea in the concentrations currently in clinical use, (1% or less) but has definite 
cytotoxic effects in higher concentrations. In many of the reports, the pharmaceutical 
name lidocaine was used and it is not clear whether Xylocaine was the agent. This 
may be important in view of the observations on pH and osmolality mentioned above. 
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ACTIONS OF XYLOCAINE (LIDOCAINE)  
Xylocaine has a well known reputation as a safe local anaesthetic for injection and 
topical use. It has interesting effects on cell viability, reducing respiration and 
dehydrogenase activity and this effect is explored in the clinical series reported here.  
IN VITRO  
It has been noted for a long time that the positive culture rate from clinically 
diagnosed bacterial conjunctivitis is much lower than expected. This is because local 
anaesthetics are used in the conjunctival sac before taking the culture but they have an 
antibacterial effect.(Mullin and Rubinfeld, 1997)  
Comparison of the inhibitory effects of topical proparacaine 0.5%, tetracaine 0.5% 
and cocaine 4% on Pseudomonas aeruginosa and Staphylococcus aureus was tested 
in culture over 24 hours. Cocaine had the weakest inhibition but the greatest 
anaesthesia. The authors’ suggestion that cocaine be used before taking a conjunctival 
culture is impractical in the clinic because of the need to maintain a dangerous drug 
register. Tetracaine may produce more positive cultures while giving satisfactory 
anaesthesia. (Mullin and Rubinfeld, 1997) Similarly, common pathogenic bacteria have a poor 
recovery rate in skin biopsy specimens when Xylocaine is used. (Thompson et al., 1993) 
Lidocaine 1% was not as effective as oxybuprocaine 0.2% or tetracaine 0.4% against 
48 bacterial strains using minimum inhibitory concentrations against standard 
bacterial concentrations. This is contrary to the above report but the author agreed that 
commercially available eye drops might lead to false negative bacterial cultures. 
(Labetoulle et al., 2002) 
Lidocaine 1,846 micromole, bupivacaine 770 micromole and ropivacaine 801 
micromole were tested against staphylococcus aureus suspended in human blood 
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cells. Monoclonal antibody staining was used as the test method showing that 
granulocyte capability to ingest bacteria was significantly reduced by the first two but 
not the third. No comment was made as to whether bacterial growth was inhibited or 
enhanced. (Kiefer et al., 2003) Natural killer cell inhibition by lidocaine occurs very rapidly 
at concentrations that are clinically relevant for infiltration anaesthesia. (Krog et al., 2002) 
This point becomes important in the clinical setting as local anaesthetics, usually 
Xylocaine, are sometimes mixed with solutions for intravenous use to reduce 
discomfort to the patient. A common combination of lidocaine (various 
concentrations) in the centrally acting intravenous anaesthetic propofol tested against 
E coli, S aureus, S epidermidis and P aeruginosa showed that lidocaine needed to be 
in a concentration of 2% to reduce the number of bacteria. (Oser et al., 2002), (Gajraj et al., 1999) 
Lidocaine may also be infiltrated into incisions at the end of operations to reduce 
post operative pain. Would the above findings lead to increased wound infection? 
Tested against E faecalis, E coli, P aeruginosa and S aureus in lidocaine with and 
without epinephrine demonstrated a dose dependent (1 to 4%) inhibition of growth of 
all strains especially gram-negative but least s aureus. The author recommended wider 
application of the method.(Parr et al., 1999) In contrast, lidocaine used in liposuction does 
not reach concentrations significant to inhibit the growth of commonly encountered 
bacteria.(Craig et al., 1999) 
In summary, lidocaine has a dose related toxic effect on a wide variety of cells. It acts  by 
reducing cell respiration and dehydrogenase release and reduces the desmosomal area, 
reducing cell adhesion. Its effects on the cells of the posterior capsule of the lens of the 
human eye are considered in the next chapter. 
The study in this thesis attempts some improvement in PCO rates by a 
pharmacological method that has not been reported previously. It utilises the known 
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safety of Xylocaine unpreserved 1% 1mL commonly used intraocularly with its 
known toxicity against some bacteria in this concentration. Higher volumes and/or 
concentrations can be toxic to corneal endothelial cells.  
By using the Xylocaine as hydrodissection fluid instead of balanced salt solution it was 
hoped that sufficient lens epithelial cells would be killed to reduce PCO rates. It is well 
documented that this dose does not damage the corneal endothelium and all should be 
removed from the eye during the lens removal that follows. Even if some remains, the half 
life of Xylocaine in the anterior chamber of the eye is approximately 9 minutes so that long 
term effects are unlikely. 
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Chapter Seven 
Xylocaine - the Human Experience  
Xylocaine unpreserved intraocularly is safe if infused in concentrations of 1% or 
less, a volume of 1 mL or less and especially if used underneath a viscoelastic device.  
The pH tolerance of the human cornea is 6.5 to 8.5 (Gonnering, 1979) and osmotic 
tolerance 200 to 400 mOsm/L,(Edelhauser, 1981) as discussed above. The pH of 
unpreserved Xylocaine is 5.7 approximately according to the manufacturer. 
“Preservative free lidocaine 1% may help diminish the amount of live lens epithelial 
cells by facilitating cortical cleanup, by loosening the desmosomal area of cell-cell 
adhesion with decreased cellular adherence, or by direct toxic effect”. (Vargas 2003) 
The purpose of this study was to seek empiric evidence to support the utility of 
hydrodissection with Xylocaine 1%, mL preservative free in the prevention of 
posterior capsule opacification and not to study the mechanisms whereby this may 
occur. In this context, a detailed discussion of the interaction of Xylocaine with lens 
epithelial cells is not warranted. 
Accidental injection of local anaesthetic into the eye has been recorded. A high 
standard report summarised three patients who had intravitreal injection of local 
anaesthetic inadvertently during ocular procedures. Even though these preparations 
contained epinephrine 1:100,000 there was no permanent damage to the retina. 
Retinal function was lost immediately but recovered starting in four and being 
complete within sixteen hours. One patient developed traumatic retinal damage at the 
perforation site.(Lincoff et al., 1985) Note that these good results in patients will be achieved 
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only if the perforation of the globe is recognised immediately by the surgeon or 
anaesthetist and the raised intraocular pressure which develops from the increased 
volume from the injection is treated without delay; otherwise ischaemic retinal 
damage will follow. 
These authors followed these observations by intravitreal injection in four adult cats 
using saline as control, lidocaine 2%, lidocaine 2% with epinephrine 1:100,000 and 
hyaluronidase 15 units/cc. Electroretinogram (ERG) recordings showed rapid 
extension for about four hours but full recovery by eighteen hours. Histological 
examination of the retinae at twenty-four hours showed no significant retinal damage 
from any of the three preparations.(Lincoff et al., 1985) 
Another instance of intra-cameral lidocaine injection was recorded in a patient who 
had a traumatic rupture of a penetrating corneal graft having undergone a planned 
vitrectomy previously. 0.5 cc of unpreserved lidocaine 1% was used as anaesthesia 
during the surgery and it diffused back to the retina causing temporary visual loss 
with complete recovery one day postoperatively.(Heuermann et al., 2002) 
These results were supported as an incidental observation in a study that looked at 
levels of local anaesthetic in aqueous humour following retrobulbar injection of local 
anaesthetic. Small amounts of anaesthetic do reach the aqueous humour following 
peribulbar or retrobulbar injection. These techniques have been used for many years 
and there are no records of toxicity to the cornea from these injections.(Salomon, 1990) A 
study of 1,000 eyes having cataract and intraocular lens surgery was conducted to 
determine lidocaine efficacy as anaesthesia. This study found no toxic effects to the 
eye from lidocaine unpreserved 1%.(Koch, 1997) 
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Lidocaine unpreserved 1% 0.l mL was used in a well designed prospective double 
masked study of 183 patients compared with balanced salt solution as control. 
Although the study was designed to assess efficacy as anaesthesia, the authors 
observed that in neither group was there significant endothelial cell loss or other 
adverse event.(Gills et al., 1997) These findings were confirmed by a series of 80 patients 
using 0.3 mL unpreserved lidocaine 1% against a control of normal saline.(Roux, 1998)  
Safety was also confirmed by a number of studies using preservative free lidocaine 
1% up to 0.5 mL volume showing that specular microscopy and/or computer assisted 
morphometry showed no increase in the corneal endothelial cell loss or mean cell size 
in the short term. There is always some endothelial cell loss in any intraocular 
surgery.(Garcia et al., 1998, Martin, 1998, Maskett and Gokomen, 1998, Elvira et al., 1999)  
A study that looked at 200 consecutive cataract surgeries compared 0.15 mL of 
intracameral 1% unpreserved lidocaine with patients who had parabulbar anaesthesia. 
The flash electroretinogram (ERG) was also evaluated in this study. There was no 
statistically significant difference to the transient suppression of the erg between the 
groups and all recovered fully.(Anders, 1999)  
A single centre, prospective, randomised, double masked study comparing 0.5 mL 
unpreserved lidocaine 1% with balanced salt in 190 patients undergoing cataract 
surgery set out to assess whether the additional intraocular anaesthesia was superior to 
drops of tetracaine only preoperatively. The authors concluded that there was little 
difference in pain but did note that although there was no evidence of corneal 
endothelial toxicity in the short term, the long term studies were not available at that 
time and urged caution in the use of the procedure.(Boulton et al., 2000) 
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As mentioned in previous chapters it is important to use an agent which has pH and 
osmolarity close to isotonic. A report of corneal endothelial haze immediately after 
injection of generic lidocaine product showed that it was hypotonic with an 
osmolarity of 129 mOsm/L and a pH of 5.06. This hypotonicity was potentially 
damaging to the corneal endothelium. The manufacturer’s data sheets did not record 
these parameters. (Spalton, 2000) These facts must be obtained prior to intraocular use of 
any generic product. Pharmacists may not check these parameters when searching for 
the cheapest supplier. This step is extremely important and neglect would possibly be 
culpable. 
Blood-aqueous barrier (BAB) permeability was studied in 60 patients having 
uneventful cataract surgery comparing sub-tenon’s anaesthesia with 0.2 mL of 1% 
preservative free lidocaine. It was concluded that the BAB permeability one month 
after surgery had recovered. No additional inflammation was induced by the 
intraocular lidocaine. Endothelial cell morphology was also not compromised.(Iradier et 
al., 2000) 
A further study of 67 patients having cataract surgery with intraocular unpreserved 
lidocaine 1% 0.3 mL compared to a placebo found no toxic effects from the lidocaine 
in the short term.(Roberts and Boytell, 2002) 
Similar findings of no untoward events using 0.5 mL of preservative free 1% 
Xylocaine in the anterior chamber were found in a study that was designed to assess 
the pupil dilating effect without preoperative eye drops.(Cionni et al., 2003) This result was 
supported in the study of 30 patients without and 27 with intracameral lidocaine 1% 
0.5 mL.(Nikeghbali et al., 2007) 
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Lidocaine mixed with mydriatics was injected intracamerally in 60 patients to try to 
avoid preoperative drops. “The corneal cell loss in our study is in accordance with 
that reported in modem phacoemulsification surgery”. This study also shows that 
there is no negative interaction between Xylocaine 1% and pupil dilating substances. 
(Lundberg and Behndig, 2003) Whether the combination was more effective than either alone 
was not noted. 
The long term effect on corneal endothelial safety was addressed in a study of fifty-
three patients using Xylocaine 0.2 mL 1% preservative free compared to controls and 
followed for twelve months. Using specular microscopy and ultrasound corneal 
pachymetry it was concluded that “intracameral preservative free 1% Xylocaine does 
not appear to effect the corneal endothelium during phacoemulsification”.(Shah, 2004) 
Similar results at twenty months after surgery using specular microscopy were found 
in 78 eyes comparing 0.15 mL of unpreserved lidocaine 1% with peribulbar 
anaesthesia.(Heuermann et al., 2002) 
Systemic levels of lidocaine after intracameral injection of 0.5 mL 1% preservative 
free was studied in ten patients. It revealed no systemic therapeutic concentrations so 
that the technique would be safe for patients in whom the anti-arrhythmic effects of 
Xylocaine may be contra-indicated.(Wirbelauer et al., 1999)  
An extensive report by the American Academy of Ophthalmology on the 
effectiveness of intracameral anaesthesia summarised the published literature in 2001. 
It noted  “short term studies seem to indicate that preservative free lidocaine 1% up to 
a dose of 0.5 mL is well tolerated by the corneal endothelium in the short term”. 
There was no evidence at that time of the effects of higher concentrations.(Karp et al., 2001)  
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Pharmacodynamics of lidocaine in the eye was studied in both rabbits and humans. 
This showed rapid uptake of radioisotope labelled 1% Xylocaine into the ciliary body 
but also a rapid washout with half life of nine minutes with no metabolites 
detected.(Anderson et al., 1999) 
Toxic anterior segment syndrome (TASS) was reported in three patients when 1% 
Xylocaine 1.5 mL was used for hydrodissection. It was recommended that the volume 
used should not exceed 1 mL.(Gills, 2004) The cause of the TASS was attributed to the 
Xylocaine but they were a small number in a large series and being postoperative 
there was no opportunity to analyse the ampoules used, as they had already been 
disposed. The clinical safety of intracameral lidocaine was summarised by an 
evidence based medicine supporter. “the clinical toxicity is negligible, the cost is 
extremely low”.(Schuster, 2001) 
 
SUMMARY  
The short term safety to the corneal endothelium of intracameral Xylocaine 1% 
unpreserved in humans during routine phacoemulsification is well established and 
two long term studies support this as well as extensive clinical experience. In the 
study reported herein, the volume of 1% preservative free Xylocaine was limited to l 
mL and it was used underneath a viscoelastic protecting the cornea. The lack of 
untoward events in this series also confirms its safety.  
Xylocaine was used because of its extensive clinical experience and well established 
safety record and consistent pharmacological composition when compared to other 
preparations of lidocaine especially generic ones. 
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CHAPTER EIGHT 
Materials and methods  
STUDY DESIGN. 
The concept is to assess the incidence of PCO after cataract surgery with IOL 
implantation comparing hydrodissection with conventional balanced salt solution 
against unpreserved Xylocaine 1% 1mL. 
Generic preparations vary in their specifications and were not used in this reported 
series for safety reasons and for consistency. In some of the research papers quoted, it 
is not stated whether the lidocaine reported was generic or specific. 
PATIENT RECRUITMENT. 
All surgery was performed by the author at Calvary Hospital, Bruce, Australian 
Capital Territory and Calvary John James Hospital, Deakin, Australian Capital 
Territory. Ethics committee approval was obtained from each hospital authority prior 
to commencement (HREC ref 10-2004; and 03/11.2004). Surgical technique and IOL 
design was standardised throughout. All patients with uncomplicated cataract on the 
surgical list at each hospital were included in the prospective cohort of the series 
starting 01.01.03. A retrospective balanced cohort was used for comparison extending 
back up to 8 years. 
SURGICAL TECHNIQUE. 
After a full ophthalmological examination, the need for cataract surgery including 
risks was discussed with the patient. Cataracts other than of senile cause were not 
included in this series. All patients had an anaesthetic block of the anaesthetist’s and 
patient’s choice. At surgery, a sclerocorneal incision using a 2.65mm keratome was 
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made. Viscoelastic was introduced into the anterior chamber using the two 
components of ‘Duovisc’ (Alcon, Sydney, Australia) in a soft shell technique. 
Anterior capsulorhexis of 5-6 mm was performed with either a needle or with the 
author’s design of multi function capsulorhexis forceps. Hydrodissection was 
performed in at least two sites using either the standard balanced salt solution or 
Xylocaine unpreserved 1% 1 mL. If a further volume of fluid was needed for 
complete rotation of the lens nucleus in the Xylocaine group, balanced salt was used. 
Phacoemulsification was performed with two side ports using either the Millenium 
machine (Bausch and Lomb) or the Sovereign (AMO) and a Kelman style angled 
microflow-plus needle in both. Irrigation-aspiration of the remaining material was 
done with automated bimanual technique. In all cases, foldable lens (AMO ar40e) 
was inserted in the bag and all viscoelastic was aspirated leaving the eye at a normal 
pressure. Sutures were not used routinely. No attempt to assess pain relief was made 
in this series.  
The patients were assessed at a minimum of one day, one week and three weeks post 
operatively and then as clinically necessary and were routinely re-assessed at one year 
unless they requested earlier review. 
The need for posterior capsulotomy by Nd:YAG laser was assessed after ruling out 
other reasons for reduced vision although capsulotomy was done in some patients 
with multiple causations of loss of best corrected visual acuity post operation. 
Another surgeon who had not been involved with the patient previously then 
independently reassessed the need for capsulotomy and performed all the laser 
treatments as indicated. Capsulotomy was not done unless the vision was reduced by 
at least 1 Logmar line beyond their best corrected post operative acuity and the patient 
was symptomatic Subsequent follow up depended on clinical need. 
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There were 842 eyes in the control group and 692 in the Xylocaine group totalling 
1534. Age and sex distribution are in Tables 3 and 4 and are comparable. 
There was no change in postoperative progress between the two groups. 
STATISTICAL ANALYSIS. 
This was conducted independently by Dr K Dear, Australian Centre for 
Epidemiology and Health, Australian National University. The methodological details 
are in Chapter 9 to avoid replication and to enhance readability. 
 
 
72 
CHAPTER NINE 
Results of the current study 
The author used identical surgical technique and the same IOL and performed all 
surgeries. The single variable was the substitution of Xylocaine 1% 1 mL unpreserved 
for hydrodissection for the routine balanced salt solution. Time from IOL to Nd:YAG 
varied from 33 days to over 8 years. 
STATISTICAL METHOD  
The data was analysed using Cox regression, with date of IOL as a covariate. A 
nonparametric smooth curve was fitted (natural spline with 4df) plus a two-level 
factor distinguishing IOL operations done before and after 1/1/2003. The last 
Nd:YAG laser operation on a patient in the study took place on 21/8/2007 (that 
patient’s IOL was dated 9/12/2004). Patients who had not required Nd:YAG 
treatment by then were ‘censored’ at that date for purposes of time-to-failure analysis 
(“survival analysis”). Analysis was done using stata 9.2. 
(http://www.ststa.com/support) 
RESULTS  
Of 842 IOL operations prior to the change over date of 1/1/2003, 155 have required 
Nd:YAG (18%). Of 692 subsequently, 26 have required Nd:YAG (4%). However, as 
Figure 11 shows, this percentage was already declining steeply before 2003, and rose 
slightly in 2004 (data for 2005 are incomplete). Figure 10 shows the percentage of 
patients requiring Nd:YAG within two years of the operation (data for 2005 are 
incomplete).  
 
73 
 
 
TABLE 2 – ND:YAG REQUIRED IN THE SERIES 
      YEAR |        NO        YES |     TOTAL 
      1998 |        55         27 |        82  
          %|     67.07      32.93 |    100.00  
           |                      | 
      1999 |        97         32 |       129  
         % |     75.19      24.81 |    100.00  
           |                      | 
      2000 |        95         36 |       131  
         % |     72.52      27.48 |    100.00  
           |                      | 
      2001 |       211         38 |       249  
         % |     84.74      15.26 |    100.00  
           |                      | 
      2002 |       233         22 |       255  
         % |     91.37       8.63 |    100.00  
           |                      | 
      2003 |       264          8 |       272  
         % |     97.06       2.94 |    100.00  
           |                      | 
      2004 |       251         14 |       265  
         % |     94.72       5.28 |    100.00  
           |                      | 
      2005 |       151          4 |       155  
         % |     97.42       2.58 |    100.00 
 
 
  TABLE 3 – AGE DISTRIBUTION (YEARS) 
TREATMENT MEAN MEDIAN RANGE
SALINE (PRE 
1/1/2003) 
75 77 40-96 
XYLOCAINE 
(POST 1/1/2003) 
76 77 41-97 
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  TABLE 4 – SEX DISTRIBUTION 
TREATMENT FEMALES MALES TOTAL 
Saline (pre 
1/1/2003) 
546 296 842 
PERCENTAGE 64.85 35.15 100.00 
XYLOCAINE 
(POST 1/1/2003) 
428 264 692 
PERCENTAGE 61.85 38.15 100.00 
TOTAL 974 560 1,534 
PERCENTAGE 63.49 36.51 100.00 
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    FIGURE 10 – PERCENTAGE REQUIRING ND:YAG WITHIN  
TWO YEARS 
 
Figure 10. Percentage of patients requiring posterior capsulotomy by laser at 2 years 
post op. The data for year 2005 are incomplete.
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FIGURE 11 – RELATIVE RISK OF REQUIRING ND:YAG 
Figure 11 shows the relative risk of requiring Nd:YAG relative to the minimum 
(optimum) time in early 2004. The model permitted a step change at 1/1/2003, 
coinciding with the introduction of Xylocaine. The estimated change at this date is 
not statistically significant (p=0.855). Figure 12 shows the (very similar) result of 
fitting the same model, but ignoring the change at 1/1/2003. 
FIGURE 12 – AS FIGURE 11 BUT BY DATE WITH NO 
DISCRETE CHANGE IN RISK AT 1/1/2003 
 
Figure 12 – Relative risk of requiring Nd:YAG by date of IOL. Grey bands are 
95% ci. Coloured tickmarks show dates of IOL (below) and of Nd:YAG (above). 
Yellow=saline; green=Xylocaine. P=0.855 for the step at 1/1/2003: not 
statistically significant. Patients with IOL operations performed after august 2005 
are not included. 
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CONCLUSION  
There was a strong trend of reducing risk from 1999 to 2004, with a seven-fold risk 
difference between the highest and lowest points on the curve. There is no evidence 
of any effect from the 1/1/2003 introduction of Xylocaine 1% unpreserved 1 mL 
during IOL operations. 
The slight rise in 2004, noted in Figure 10 and already identified in the results, did 
not achieve significance in the modelling. The modelling is accepted, as the basis for 
the conclusion that improved operator effect is the most likely explanation for what at 
first sight appears to be a positive effect of Xylocaine. The 2004 results do not distort 
the overall model and the conclusions drawn from it. 
The original concept by the author of using a known safe drug in a novel way did 
not result in any statistical improvement in PCO occurrence in this series and had no 
untoward effects.  
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CHAPTER TEN 
DISCUSSION 
Posterior capsule opacification after cataract extraction and intraocular lens 
extraction is a continuing problem for patient and surgeon even though rates are 
reducing world wide with improvements in surgical technique and IOL design and 
materials. 
Pharmacological methods of reducing PCO will become more important in the 
future with the introduction of new styles of IOLs (such as accommodating) that do 
not appose the posterior capsule and in refractive lens exchange. These operations 
depend on a permanently clear capsule in every case and capsulotomy may perhaps 
threaten the stability of the IOL. 
The author chose to utilise the known safety to the corneal endothelial cells of 
Xylocaine unpreserved1% 1mL and its lesser known cellular toxicity in a way 
previously unreported. A prospective group of 842 patients with uncomplicated 
cataracts was taken in order off the hospital surgery waiting lists and was matched 
with an age and sex balanced group of 692 retrospectively. A small number of 
patients required extra fluid in the form of BSS for adequate hydrodissection. It was 
felt that this did not invalidate the hypothesis because of the short half life of 
Xylocaine in the eye. 
The end point for YAG laser posterior capsulotomy was taken as the symptomatic 
loss of best corrected post operative visual acuity of at least one Logmar line. An 
independent ophthalmologist who had not previously been involved with these 
patients and who performed all the treatments reassessed the need for YAG. No toxic 
effects from the Xylocaine were noted. 
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An expert statistician then assessed statistical analysis again independently. His 
conclusion was that the trial of Xylocaine hydrodissection showed no improvement as 
compared with the author’s trend line (which was also consistent with world wide 
trends)  
In the continuing search for a substance that will kill lens epithelial cells and not 
corneal endothelial cells, Xylocaine unpreserved 1% 1 mL is shown to be the safest. 
Higher concentrations are not proven to be safe and in some cases are toxic in a dose 
related fashion. Larger volumes may not be toxic because of the short half life but are 
not proven safe. Xylocaine kills cells by reducing respiration and dehydrogenase 
levels and reducing desmosomal area thus reducing adhesion. 
Incorporating Xylocaine into a hydrophilic IOL as a sustained release delivery 
mechanism as described above for 5FU has not been explored in humans but should 
be safe at a release dose to be determined. 
5FU is cheap and is effective at a dose perhaps 33 mg/mL which may be toxic to the 
corneal endothelium. Use in a sealed capsule irrigation device should be safe and the 
technique should be able to establish a minimum inhibitory dose and concentration 
for this and for other substances including some of the above substances (chapter 5). 
These can be tested in vitro and later in vivo. 
 In the future, elegant methods of preventing lens epithelial cell proliferation such as 
immunotoxins and gene therapy may prove to be safe and effective in clinical 
practice. More evidence is needed particularly which toxins and which genes even 
though some are currently under investigation. A suggestion that growing the 
patient’s own lens epithelial cells and reinjecting them into the capsular bag is 
probably impractical in view of a time lag that would be unacceptable to the patient. 
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APPENDIX 
•  
                                                               John James  
 Memorial Hospital  
 
 Strickland Crescent, DEAKIN ACT 2600  
 PO Box 23, DEAKIN WEST ACT 2600  
 Telephone (02) 6281 8100  
 Facsimile (02) 6281 8168  
 www.jjmh.com.au  
 ACN 008 453 469  
 
03/11/2004 
Dr Thomas D. Walker  
PO Box 3171 MANUKA  
ACT 2603  
 
Dear Dr Walker  
 
Re: Potential Paper for Publication  
The John James Memorial Hospital Ethics Committee, at its meeting on 28th of October 2004, 
noted your letter and feel that there is no ethical problem given that you already had the data 
outside the usual requirements of confidentiality. There are no further questions at this time.  
Yours sincerely  
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Dr Tom Faunce 
Chairman Ethics Committee 
 
 
 
 
 Calvary  
 Health Care  
 ACT 
 
10 October 2006  
 
 
Dr Tom Walker 
c/- Post Office  
Yarralumla  
ACT 2600  
 
.Dear Dr Walker  
 
Re: The effect of hydro dissection in cataract surgery with Lignocaine 1 % plain (HREC ref: 10-
2004)  
 
 
I am writing on behalf of the Calvary Health Care ACT Human Research and Ethics Committee to 
request a brief progress report on the above-named study. Please note that the NH&MRC's guidelines on 
Ethical Conduct in Research Involving Humans require that reports be provided at least annually. It 
would be appreciated if you could ensure that we receive your report by 20 October to enable it to be 
tabled at the next meeting of the HREC.  
 
Annual reports should include the following information:  
 
• Progress to date (or outcome in the case of completed research)  
• Maintenance and security of records  
• Compliance with the approved protocol  
• Compliance with any conditions of approval  
 
The HREC also requires an immediate report in any of the following events:  
 
• Any serious or unexpected adverse effect on participants  
• Any proposed changes to the protocol  
• Any unforeseen events that might affect continued ethical acceptability of the project  
• Discontinuation of the project before the expected date of completion  
 
I look forward to receiving your report in due course.  
 
Yours sincerely  
 
 
Tricia Ewing  
Manager, Human Research & Ethics Committee  
 
 
Calvary Health care ACT 
Limited  
ABN 74105 304 989  
PO Box 254 
Jamison Centre 
ACT 2614  
Ph: 026201 6111 
Fax: 02 6201 6210  
wwv.~calvary-act.com.au  
LOCATIONS  
Calvary Public Hospital 
Calvary Private Hospital 
Calvary Clinic  
Calvary Foundation  
Cnr Belconnen Way  
and Haydon Drive  
Bruce ACT 2617  
Clare Holland House 
(ACT Hospice) Menindee 
Drive Barton ACT 2600  
Ph: 02 6273 0336  
Fax: 02 6273 0338
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Services of the Sisters of the Little Company of Mary  
with values of hospitality, healing, stewardship and respect  
Calvary Public Hospital I Calvary Private Hospital I ACT Hospice | Calvary Clinic | Calvary Foundation  
Two fully accredited hospitals - Public and Private  
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ABSTRACT 
Reduction of Posterior Capsule Opacification (PCO) after cataract surgery has been 
achieved since the general acceptance of posterior chamber intraocular lens implantation 
thirty years ago. Attention to surgical technique on one hand and changes in lens design and 
materials on the other, have synergistically reduced the incidence of PCO to less than 5% at 
5 years. But lens epithelial cells still proliferate and pharmacological prevention has so far 
been largely unsuccessful. Any agent must be toxic to these lens epithelial cells without 
being toxic to the corneal endothelium. This review looks at many substances that have 
been tried and a few that have been partly successful without yet entering clinical practice. 
Possibilities for future clinical research are canvassed. 
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